Merck, through an affiliate, has extended its research collaboration with Idera Pharmaceuticals, Inc. for a fourth year. The companies entered into an exclusive license and research collaboration in December 2006 to develop and commercialize vaccine products containing agonist compounds targeting Toll-like Receptors (TLRs) in the fields of oncology, infectious diseases, and Alzheimer’s disease. As part of the agreement, the companies engaged in a two-year R&D collaboration to generate no...